Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
12–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a documented diagnosis of persistent asthma and who were currently treated with or qualified for treatment with both ICS and long-acting beta2-agonist (LABA) combination
Patients demonstrating an increase in forced expiration volume in 1 second (FEV1) of ≥ 12% or ≥ 200 mLs within 30 minutes after administration of short-acting beta2-agonist (SABA)
Patients with an FEV1 ≥ 50% of predicted normal
You may not be if
Patients with a previous diagnosis of chronic obstructive pulmonary disease (COPD)
Patients who had an asthma attack/exacerbation requiring hospitalization/emergency room visit or respiratory tract infection within 1 month prior to randomization
Patients who had ever required ventilator support for respiratory failure
Patients with diabetes Type I or uncontrolled diabetes Type II
Patients with concomitant pulmonary disease
Patients with certain cardiovascular co-morbid conditions
Patients with any significant medical condition that might compromise patient safety, interfere with evaluation or preclude completion of the study
Clareo Health | Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
